 |
|
 |
|
|
|
Laurell CB,
Eriksson S. |
The electrophoretic α¹ globulin pattern of serum in α¹antitrypsin deficiency. |
Scand J Clin Lab Invest. 1963;15:132-140. |
|
Sharp HL,
Bridges RA,
Krivit W,
Freier EF. |
Cirrhosis associated with alpha-1-antitrypsin deficiency: a previously unrecognized inherited disorder |
J Lab Clin Med. 1969;73:934-939. |
|
| Janoff A, Scherer J. |
Mediators of inflammation in leukocyte lysosomes. IX. Elastinolytic activity in granules of human polymorphonuclear leukocytes. |
J Exp Med. 1968;128:1137-1155 |
|
Wewers MD,
Casolaro MA,
Sellers SE,
Swayze SC,
McPhaul KM,
Wittes JT,
Crystal RG. |
Replacement therapy for alpha¹-antitrypsin deficiency associated with emphysema |
N Engl J Med. 1987;316:1055-1062. |
|
Lomas DA,
Evans DLI,
Finch JT,
Carrell RW. |
The mechanism of Z α¹-antitrypsin accumulation in the liver. |
Nature. 1992;357:605-607. |
|
Seersholm N,
Wencker M,
Banik N,
Viskum K,
Dirksen A,
Kok-Jensen A,
Konietzko N, for the
Wissenschaftliche
Arbeitsgemeinschaft
zur Therapie von
Lungenerkrankungen
(WATL) α¹AT study
group |
Does α¹antitrypsin augmentation therapy slow the annual decline in FEV¹ in patients with severe hereditary α¹ antitrypsin deficiency |
Eur Respir J. 1997;10:2260 |
|
The Alpha
-1-Antitrypsin
Deficiency
Registry Study
Group. |
Survival and FEV¹ decline in individuals with severe deficiency of α¹ antitrypsin. |
Am J Respir Crit Care Med. 1998;158:49-59. |
|
Wencker M,
Banik N,
Buhl R,
Seidel R,
Konietzko N, for the
Wissenschaftliche
Arbeitsgemeinschaft
zur Therapie von
Lungenerkrankkungen
(WATL) α¹AT-study
group. |
Long-term treatment of α¹ antitrypsin deficiency-related pulmonary emphysema with human α¹ antitrypsin. |
Eur Respir J. 1998;11:428-433 |
|
Stockley RA,
Bayley DL,
Unsal I,
Dowson LJ. |
The effect of augmentation therapy on bronchial inflammation in α¹ antitrypsin deficiency. |
Am J Respir Crit Care Med. 2002;165: 1494-1498. |
|
Silverman EK,
Miletich JP,
Pierce JA,
Sherman LA,
Endicott SK,
Broze GJ, Jr.,
Campbell EJ. |
Alpha-1-antitrypsin deficiency. High prevalence in the St. Louis area determined by direct population screening. |
Am Rev Respir Dis. 1989;140:961-966. |
|
| Stoller JK, Smith P, Yang P, Spray J. |
Physical and social impact of alpha¹-antitrypsin deficiency: results of a survey. |
Cleve Clin J Med. 1994;61:461-467 |
|
Campos MA,
Wanner A,
Zhang G,
Sandhaus RA, |
Trends in the diagnosis of symptomatic patients with α¹ antitrypsin deficiency between 1968 and 2003. |
Chest. 2005;128:1179-1186 |
|
American
Thoracic Society. |
Guidelines for the approach to the patient with severe hereditary alpha-1-antitrypsin deficiency. |
Am Rev Respir Dis. 1989;140:1494-1497 |
|
American Thoracic
Society/European
Respiratory Society
Statement |
Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. |
Am J Respir Crit Care Med. 2003;168:818-900. Executive Summary |
|
|
Important Safety Information
Prolastin®, Alpha1-Proteinase Inhibitor (Human) is indicated for chronic replacement therapy of individuals having congenital deficiency of alpha-1 PI (alpha1-antitrypsin deficiency) with clinically demonstrable panacinar emphysema. Weekly Prolastin® therapy has demonstrated a low occurrence of side effects. In clinical studies with Prolastin®, reactions were observed in 1.16% of infusions, the most common events being fever (0.77%), light-headedness (0.19%), and dizziness (0.19%). As with all plasma-derived therapeutics, the potential to transmit infectious agents cannot be totally eliminated. Individuals with selective IgA deficiencies who have known antibody against IgA (anti-IgA antibody) should not receive Prolastin®, since these patients may experience severe reactions, including anaphylaxis, to IgA which may be present.
You are encouraged to report negative side effects of prescription drugs
to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please click here for Prolastin® full Prescribing Information.
Remember, your doctor or healthcare provider is the single best source of information regarding you and your health. Please consult your doctor or healthcare provider if you have any questions about your health or any of your medications.
|
|
|
|
|